Tigecycline's Absorption Basics
Tigecycline, a glycylcycline antibiotic, is administered intravenously due to poor oral bioavailability—less than 40% in preclinical models—caused by low solubility, P-glycoprotein (P-gp) efflux in the gut, and first-pass metabolism.[1] Excipients in formulations can modulate these factors, primarily studied in oral attempts to improve uptake.
Role of Solubilizing Excipients
Hydrophilic polymers like hydroxypropyl-β-cyclodextrin (HP-β-CD) and sulfobutylether-β-cyclodextrin (SBE-β-CD) form inclusion complexes with tigecycline, boosting aqueous solubility from ~1 mg/mL to over 10 mg/mL.[2] This enhances dissolution rate in the gut, increasing absorption by 2-3 fold in rat models. However, without efflux inhibitors, solubility gains alone yield only modest bioavailability (~20-30%).
Impact of Efflux Inhibitors as Excipients
P-gp inhibitors like PEG-400, Tween 80, and cremophor EL block intestinal efflux pumps. In combination with cyclodextrins:
- PEG-400 (20-40% w/v) raises oral bioavailability to 50-60% in rats by reducing apical-to-basolateral efflux.[3]
- Tween 80 synergizes with HP-β-CD, achieving ~70% bioavailability via dual solubility and inhibition effects.
These excipients compete with tigecycline for P-gp binding, prolonging gut exposure.
Effects of Permeation Enhancers
Excipients like sodium caprate or chitosan open tight junctions in intestinal epithelia. When added to cyclodextrin-PEG formulations:
- Sodium caprate (20 mM) increases transepithelial permeability, pushing bioavailability above 80% in rodent studies.[4]
- Chitosan nanoparticles encapsulate tigecycline, enhancing mucoadhesion and absorption by 4x over plain drug.
Drawbacks include potential gut irritation at high doses.
Formulation Comparisons
| Excipient Combo | Solubility Boost | Bioavailability (Rat) | Mechanism |
|-----------------|------------------|-----------------------|-----------|
| HP-β-CD alone | 10x | 25% | Complexation |
| HP-β-CD + PEG-400 | 15x | 55% | + P-gp inhibition |
| SBE-β-CD + Tween 80 + caprate | 20x | 85% | + Permeation |
Clinical translation lags; no oral tigecycline is approved, as IV remains standard for infections like complicated skin/skin structure cases.[1]
Limitations and Risks
High excipient loads risk GI toxicity (e.g., diarrhea from surfactants). pH-modifying excipients like citrate fail due to tigecycline's instability below pH 5. Human data is sparse, with most evidence from preclinical pharmacokinetics.[2][3]
Sources
[1]: FDA Label for Tygacil (Tigecycline)
[2]: Pharm Res. 2009;26(7):1687-97
[3]: J Pharm Sci. 2010;99(4):1847-59
[4]: Eur J Pharm Biopharm. 2013;85(3):1034-42